Close menu




November 18th, 2020 | 10:04 CET

Plug Power, Almonty, Va-Q-Tec - take advantage of these special situations!

  • Investments
Photo credits: pixabay.com

As a result of the astonishing rise in market prices since the Corona low in March of this year, not only tech stocks such as Amazon, Apple or Google but also, stocks from future industries such as hydrogen, fuel cell technology or electromobility, benefited. In addition to the share prices, the Companies' future forecasts also rose. Here is where the gravity of the situation diverges, in addition to promising business models, one needs one more thing - capital!

time to read: 3 minutes | Author: Stefan Feulner
ISIN: CA0203981034 , US72919P2020 , DE0006636681

Table of contents:


    Like at Thanksgiving

    The US fuel cell manufacturer, Plug Power, has seized the opportunity. After the share price was still below USD 2.60 in March 2020, the stock was able to participate disproportionately in the industry hype. The closing price on Monday was USD 25.00, an almost tenfold increase. After the close of the stock exchange, the management dropped the bomb. With the issuance of a total of 38 million shares at a price of USD 22.25, the Americans secured a capital inflow of no less than USD 970.0 million. According to dealer circles, the new shares have been placed, and placement is officially scheduled to be completed on November 19, 2020.

    Ambitious goals are getting closer

    With this massive injection of money, the announced targets are to be attacked. The forecasts were announced as part of the Q3 figures last week. The management expects an increase in sales to USD 412 million for the year as a whole. However, EBIT should still be deep red at minus USD 33.3 million. The leap into the profit zone, with an increase of USD 10.0 million is not expected until 2022. The jumps in sales, however, are enormous. In 2022, the sales target is USD 573 million; in 2024, the sound barrier of one billion to USD 1.2 billion is expected.

    Following this message, Plug Power corrected entirely naturally to the capital increase level. This measure could cause the stock to run out of steam in the short term. A relapse to the resistance zone at USD 19.00 is entirely possible. In the long term, however, this smart timing of the management offers significant room for improvement.

    On the home stretch

    The Canadian Company Almonty Industries, which operates two tungsten mines in Spain and Portugal, has already taken a significant step forward. They are close to completing the mega-project, namely the world's largest tungsten mine in Sangdong, South Korea. The mine could then be responsible for 5% of global tungsten production and cover 30% of production outside China. 80% of the tungsten produced worldwide still comes from China.

    Well above the global average

    According to analysts at First Berlin, the mine operated in Sangdong is "the best tungsten project in the world". Sangdong has a life span of several decades and the resource to investment ratio is very competitive at 3.9x. Also, the average tungsten content in Sangdong is 0.44%, twice the Chinese and global average. Due to the potential, the experts award a "buy" with a target price of CAD 1.45, a significant premium to the current price of CAD 0.62.

    Financing almost completely

    Besides a commitment of USD 75 million from KFW - IPEX Bank for the further development of Sangdong, which is 100% owned by Almonty, only the remaining amount of the equity component of USD 23 million is still missing. This remaining amount would be equivalent to the rise from junior to a mid-cap mining Company. CEO Lewis Black commented on the release of the Q3 figures: "Despite the numerous COVID-19 related delays and difficult negotiations, we are pleased to be able to issue the final press release on the financing of our Sangdong project shortly. In the meantime, construction work has started on site. 120 meters of the Monty B portal are almost complete, followed by the second phase of the 600-meter mine development, which will continue from the portal."

    The solution to the problem

    Even if it always sounds macabre, there are winners in the Corona crisis. The Mainz-based vaccine manufacturer, BioNTech, announced last week the successful data from the pivotal Phase 3 clinical trial for its vaccine candidate BNT162b2. The potential vaccine achieved an efficacy rate of more than 90% seven days after the second dose. Emergency approval in the US can likely be applied for as early as the end of November. So far, so good. The challenge with the first available vaccine is that it requires arctic temperatures of minus 70 degrees Celsius during transport and logistics to ensure its efficacy. Also, the vaccine can only be kept in the refrigerator and for one day only.

    Moderna message not important

    Profiteer of this problem is the Würzburg Company, va-Q-tec. This Company produces, among other things, thermoboxes and containers for the transport of temperature-sensitive goods. Just last week, an agreement was signed with a global top pharmaceutical manufacturer. According to the Company, the volume of the order should be in the high single-digit million range. The European Commission alone has pre-ordered 200 million doses of the BioNTech vaccine for this year. According to a statement by the management at the currently ongoing virtual equity forum, 3.3 billion doses of the vaccine could be transported globally in 2021 according to current calculations. The potential for va-Q-tec seems unlimited, no matter what the customers' names are.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read